PRFX 0.79 PainReform Ltd.
| Range: | 0.531-20.16 | Vol Avg: | 433626 | Last Div: | 0 | Changes: | 0.04 |
| Beta: | 0.54 | Cap: | 0.00B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Tue Sep 01 2020 | Empoloyees: | 7 | ||
| CUSIP: | M77798102 | CIK: | 0001801834 | ISIN: | IL0011651580 | Country: | IL |
| CEO: | Mr. Ilan Hadar M.B.A. | Website: | https://www.painreform.com | ||||
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow